Present and future pharmacotherapy for heart failure.

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Current heart failure (HF) pharmacotherapy guidelines recommend diuretics, ACE inhibitors (ACEIs), beta-blockers, and digitalis.
• Optimizing ACEI dosage, such as lisinopril, can enhance therapeutic benefits in HF.
• Selective angiotensin receptor-1 (AT(1)) antagonists offer an alternative for patients intolerant to ACEIs and may provide cumulative benefits when used concurrently.

Purpose of the Study:

• To review current and emerging pharmacotherapies for heart failure (HF).
• To evaluate the efficacy and optimal use of various drug classes in HF management.
• To identify potential novel treatments for decompensated and chronic HF.

Main Methods:

• Review of current American College of Cardiology and American Heart Association guidelines for HF pharmacotherapy.
• Analysis of clinical trial data on ACE inhibitors, AT(1) antagonists, beta-blockers, digitalis, and newer agents.
• Evaluation of evidence for drugs like spironolactone, carvedilol, levosimendan, amiodarone, and nesiritide in different HF stages and conditions.

Main Results:

• Optimizing ACEI dose (e.g., lisinopril) improves HF outcomes.
• AT(1) antagonists are effective alternatives and potential adjuncts to ACEIs.
• Specific beta-blockers (carvedilol, metoprolol, bisoprolol) reduce mortality in severe HF; others like celiprolol and bucindolol do not.
• Spironolactone shows benefit in advanced HF and warrants study in less severe HF and with beta-blockers.
• Digitalis provides inotropic support without mortality benefit; phosphodiesterase inhibitors are associated with increased mortality.
• Levosimendan may aid hospital treatment of decompensated HF; amiodarone is considered for high-risk arrhythmias, potentially superseded by implantable cardioverter defibrillators.
• Nesiritide is available for decompensated HF; vasopeptidase inhibitors and endothelin-A receptor antagonists require further investigation.
• Etanercept showed no benefit in a large trial; recombinant growth hormone yielded variable results.

Conclusions:

• Current HF pharmacotherapy can be optimized through precise drug selection and dosage adjustments.
• Evidence supports the use of specific ACEIs, AT(1) antagonists, and beta-blockers for improving HF outcomes and reducing mortality.
• Further research is needed for novel agents, while some existing therapies like digitalis remain crucial for specific effects despite not impacting mortality.